Who Paid My Doc Search
Menu
Product Program year 2019 Source: CMS Open Payments

Alprolix

Drug Hematology

NDC 71104-911-01

Open in the dashboard

General payments

$3,382,801

295 payments

Research payments

$165,879

260 payments

Through program year 2019, $3,382,801 in general payments and $165,879 in research payments were reported against Alprolix (Hematology).

No combined total These are different kinds of money, reported under different rules. A meal and a clinical trial grant do not add up to anything meaningful, so this site does not add them.

By program year

2 rows
Year Kind Amount Payments
2019 General $3,382,801 295
2019 Research $165,879 260

Breakdown

Who paid General payments · program year 2019
  1. Bioverativ Therapeutics Inc. $3,378,838 248 payments
  2. Sanofi-Aventis U.S. LLC $3,723 39 payments
  3. Genzyme Corporation $239 8 payments
Top recipients General payments · program year 2019
  1. Brigham And Womens Hospital Teaching hospital · MA $3,116,394 92% · 1 payment
  2. Robert Sidonio Pediatric Hematology-Oncology · Atlanta, GA $45,538 1% · 41 payments
  3. Michael Guerrera Pediatric Hematology-Oncology · Washington, DC $44,035 1% · 30 payments
  4. Sandeep Rajan Hematology & Oncology · Nashville, TN $31,139 <1% · 22 payments
  5. Lynn Malec Pediatric Hematology-Oncology · Milwaukee, WI $21,775 <1% · 21 payments

The top 5 of 91 recipients; each share is of general payments naming this product in 2019.

The top 25 recipients, free in the app

Specialties paid General payments · program year 2019
  1. Pediatric Hematology-Oncology Pediatrics $176,656 70% · 46 practitioners
  2. Hematology & Oncology Internal Medicine $33,553 13% · 20 practitioners
  3. Pediatrics $30,769 12% · 7 practitioners
  4. Hematology Internal Medicine $9,992 4% · 4 practitioners
  5. Medical Oncology Internal Medicine $47 <1% · 2 practitioners

The top 5 of 11 specialties; each share is of general payments naming this product to practitioners with a specialty in 2019. Each practitioner is counted under their primary specialty.

The top 25 specialties, free in the app

Where the money went General payments · program year 2019
  1. Massachusetts $3,116,394 92% · 1 recipient
  2. Tennessee $76,692 2% · 3 recipients
  3. District of Columbia $44,035 1% · 1 recipient
  4. California $43,987 1% · 12 recipients
  5. Florida $35,722 1% · 8 recipients

The top 5 of 23 states; each share is of general payments naming this product in 2019 where a state was reported.

The top 25 states, free in the app

Records

295 general · 260 research

Every payment, record by record

Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.

What you are looking at

Manufacturers name the drug, biological or device a payment relates to. CMS does not give products their own identifiers, so a product here is assembled from how it was reported — a brand may appear under more than one spelling, and this page covers one of them rather than the brand as a whole.

Provenance

Source: CMS Open Payments · through program year 2019

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record